 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper130th MAINE LEGISLATURE
FIRST REGULAR SESSION-2021
Legislative Document No. 1293
S.P. 413 In Senate,  March  29, 2021
An Act  To Improve  Access to Certain Injectable Medications for 
Treatment of Mental Illness and Substance Use  Disorder
Reference to the Committee on Health  Coverage, Insurance and Financial Services 
suggested and ordered printed.
DAREK M.  GRANT
Secretary of the Senate
Presented by Senator CLAXTON of Androscoggin.

Page 1 - 130LR1116(01)1Be it enacted by the People of the State of Maine as follows:
2Sec. 1.  32 MRSA §13702-A, sub-§2-A, as enacted by PL 2013, c. 308, §1, is 
3 amended to read:
42-A.  Collaborative drug therapy management.  "Collaborative drug therapy 
5 management" means the initiating, administering, monitoring, modifying and 
6 discontinuing of a patient's drug therapy by a pharmacist as authorized by a practitioner in 
7 accordance with a collaborative practice agreement.  "Collaborative drug therapy 
8 management" includes collecting and reviewing patient histories; obtaining and checking 
9 vital signs, including pulse, temperature, blood pressure and respiration; and, under the 
10 supervision of, or in direct consultation with, a practitioner, ordering and evaluating the 
11 results of laboratory tests directly related to drug therapy when performed in accordance 
12 with approved protocols applicable to the practice setting and when the evaluation does not 
13 include a diagnostic component.
14Sec. 2.  32 MRSA §13702-A, sub-§28, as amended by PL 2017, c. 185, §1, is 
15 further amended to read:
1628.  Practice of pharmacy.  "Practice of pharmacy" means the interpretation and 
17 evaluation of prescription drug orders; the compounding, dispensing and labeling of drugs 
18 and devices, except labeling by a manufacturer, packer or distributor of nonprescription 
19 drugs and commercially packaged legend drugs and devices; the participation in drug 
20 selection and drug utilization reviews; the proper and safe storage of drugs and devices and 
21 the maintenance of proper records for these drugs and devices; the administration of 
22 vaccines licensed by the United States Food and Drug Administration that are 
23 recommended by the United States Centers for Disease Control and Prevention Advisory 
24 Committee on Immunization Practices, or successor organization, for administration to 
25 adults; the administration to adults by intramuscular and subcutaneous injection of drugs 
26 approved by the United States Food and Drug Administration to treat mental illness or 
27 substance use disorder; the performance of collaborative drug therapy management; the 
28 responsibility for advising, when necessary or regulated, of therapeutic values, content, 
29 hazards and use of drugs and devices; the ordering and dispensing of over-the-counter 
30 nicotine replacement products approved by the United States Food and Drug 
31 Administration; and the offering or performing of those acts, services, operations or 
32 transactions necessary in the conduct, operation, management and control of a pharmacy.
33Sec. 3.  32 MRSA §13831, sub-§5 is enacted to read:
345.  Administration of injectable drugs.  A pharmacist who meets the qualifications 
35 and requirements of section 13832 and rules adopted by the board may administer to adults 
36 by intramuscular and subcutaneous injection drugs approved by the United States Food and 
37 Drug Administration to treat mental illness or substance use disorder under the following 
38 conditions:
39 A.  Upon the order of a practitioner to dispense and administer the drug, as long as the 
40 practitioner is notified after administration is complete in accordance with section 
41 13833, subsection 3; or
42 B.  While engaged in collaborative drug therapy management pursuant to a 
43 collaborative practice agreement in accordance with the requirements of subchapter 14.
Page 2 - 130LR1116(01)1Sec. 4.  32 MRSA §13835, sub-§1, as amended by PL 2011, c. 577, §8, is further 
2 amended to read:
31.  Criteria.  Criteria for the operation of a vaccine administration clinic inside, outside 
4 or off the premises of a retail pharmacy, rural health clinic or free clinic licensed under 
5 section 13751.  The rules must require one-time board approval of the plan of operation for 
6 any vaccine administration clinics to be operated by a pharmacist or pharmacy and may not 
7 require board approval of each individual clinic; .  Criteria for the administration of drugs 
8 by intramuscular or subcutaneous injection inside, outside or off the premises of a retail 
9 pharmacy, rural health clinic or free clinic licensed under section 13751 and must require 
10 one-time board approval of the plan for the administration of drugs by intramuscular or 
11 subcutaneous injection by a pharmacist or pharmacy and may not require board approval 
12 for each administration;
13Sec. 5.  32 MRSA §13841, sub-§2, ¶D, as enacted by PL 2013, c. 308, §4, is 
14 amended to read:
15 D.  Initiate, administer, monitor, modify and discontinue drug therapy for a particular 
16 patient pursuant to the collaborative practice agreement with a practitioner who is 
17 treating the patient, as long as the action is reported to the practitioner in a timely 
18 manner as determined by rules adopted pursuant to section 13846.
19Sec. 6.  32 MRSA §13843, sub-§6, ¶A, as enacted by PL 2013, c. 308, §4, is 
20 amended to read:
21 A.  A provision that states that activity in the initial 3 months of a collaborative practice 
22 agreement is limited to monitoring drug therapy.  After the initial 3 months, the 
23 practitioner and pharmacist shall meet to review the collaborative practice agreement 
24 and determine the scope of the agreement, which may after the initial 3 months include 
25 a pharmacist's initiating, administering, monitoring, modifying and discontinuing a 
26 patient's drug therapy and reporting these actions to the practitioner in a timely manner 
27 in accordance with rules adopted pursuant to section 13846;
28SUMMARY
29 This bill permits pharmacists licensed within the State to administer to adults injections 
30 of drugs approved by the United States Food and Drug Administration for the treatment of 
31 mental illness and substance use disorder upon the order of a licensed practitioner or as part 
32 of a collaborative practice agreement.29
30
31
32
